Physician profile
Jared Smith
NPI 1356079727
$1,396.26
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $263 · 2023: $1,088 · 2024: $44.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,133.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $245.79 | 2023 | |
| Novo Nordisk INC | $195.99 | 2022-2023 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $160.27 | 2023 | Emgality, Mounjaro, Trulicity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $132.38 | 2022-2023 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $119.52 | 2022-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $105.32 | 2022-2023 | Austedo Xr, Austedo |
| Bayer Healthcare Pharmaceuticals INC. | $78.88 | 2022-2023 | |
| Amgen INC. | $66.16 | 2022-2023 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.37 | 2023 | Xifaxan, Trulance |
| Lundbeck LLC | $54.43 | 2022-2023 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.89 | 2023 | Jardiance |
| Novartis Pharmaceuticals Corporation | $29.59 | 2022-2023 | |
| Idorsia Pharmaceuticals US INC | $28.69 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.29 | 2023 | Glassia |
| Hologic Sales and Service, LLC | $18.87 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $14.81 | 2023 | Breztri |
| Glaxosmithkline, LLC. | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.